Targeting drugs to tumours using cell membrane-coated nanoparticles
- PMID: 36307534
- DOI: 10.1038/s41571-022-00699-x
Targeting drugs to tumours using cell membrane-coated nanoparticles
Abstract
Traditional cancer therapeutics, such as chemotherapies, are often limited by their non-specific nature, causing harm to non-malignant tissues. Over the past several decades, nanomedicine researchers have sought to address this challenge by developing nanoscale platforms capable of more precisely delivering drug payloads. Cell membrane-coated nanoparticles (CNPs) are an emerging class of nanocarriers that have demonstrated considerable promise for biomedical applications. Consisting of a synthetic nanoparticulate core camouflaged by a layer of naturally derived cell membranes, CNPs are adept at operating within complex biological environments; depending on the type of cell membrane utilized, the resulting biomimetic nanoformulation is conferred with several properties typically associated with the source cell, including improved biocompatibility, immune evasion and tumour targeting. In comparison with traditional functionalization approaches, cell membrane coating provides a streamlined method for creating multifunctional and multi-antigenic nanoparticles. In this Review, we discuss the history and development of CNPs as well as how these platforms have been used for cancer therapy. The application of CNPs for drug delivery, phototherapy and immunotherapy will be described in detail. Translational efforts are currently under way and further research to address key areas of need will ultimately be required to facilitate the successful clinical adoption of CNPs.
© 2022. Springer Nature Limited.
Similar articles
-
Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.Med. 2024 Jul 12;5(7):660-688. doi: 10.1016/j.medj.2024.03.012. Epub 2024 Apr 5. Med. 2024. PMID: 38582088 Review.
-
Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics.Clin Transl Med. 2021 Feb;11(2):e292. doi: 10.1002/ctm2.292. Clin Transl Med. 2021. PMID: 33635002 Free PMC article. Review.
-
Cancer Cell Membrane-Based Materials for Biomedical Applications.Small. 2024 Feb;20(7):e2306540. doi: 10.1002/smll.202306540. Epub 2023 Oct 9. Small. 2024. PMID: 37814370 Review.
-
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria.Adv Drug Deliv Rev. 2024 Jun;209:115320. doi: 10.1016/j.addr.2024.115320. Epub 2024 Apr 21. Adv Drug Deliv Rev. 2024. PMID: 38643841 Review.
-
Cell membrane-camouflaged nanoparticles for drug delivery.J Control Release. 2015 Dec 28;220(Pt B):600-7. doi: 10.1016/j.jconrel.2015.07.019. Epub 2015 Jul 23. J Control Release. 2015. PMID: 26210440 Free PMC article. Review.
Cited by
-
Capped Plasmonic Gold and Silver Nanoparticles with Porphyrins for Potential Use as Anticancer Agents-A Review.Pharmaceutics. 2024 Sep 28;16(10):1268. doi: 10.3390/pharmaceutics16101268. Pharmaceutics. 2024. PMID: 39458600 Free PMC article. Review.
-
The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.Cell Death Dis. 2023 Nov 11;14(11):734. doi: 10.1038/s41419-023-06265-2. Cell Death Dis. 2023. PMID: 37951987 Free PMC article. Review.
-
Single Low-Dose Nanovaccine for Long-Term Protection against Anthrax Toxins.Nano Lett. 2022 Dec 14;22(23):9672-9678. doi: 10.1021/acs.nanolett.2c03881. Epub 2022 Nov 30. Nano Lett. 2022. PMID: 36448694 Free PMC article.
-
CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma.Adv Sci (Weinh). 2024 Jan;11(1):e2305279. doi: 10.1002/advs.202305279. Epub 2023 Nov 15. Adv Sci (Weinh). 2024. PMID: 37968249 Free PMC article.
-
Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.J Nanobiotechnology. 2024 Oct 18;22(1):635. doi: 10.1186/s12951-024-02925-3. J Nanobiotechnology. 2024. PMID: 39420366 Free PMC article. Review.
References
-
- Gangadhar, T. C. & Vonderheide, R. H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11, 91–99 (2014). - DOI
-
- Bower, J. E. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11, 597–609 (2014). - DOI
-
- Stone, J. B. & DeAngelis, L. M. Cancer-treatment-induced neurotoxicity — focus on newer treatments. Nat. Rev. Clin. Oncol. 13, 92–105 (2016). - DOI
-
- Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013). - DOI
-
- Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299–309 (2019). - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous